1. New Drugs 2017 PART 2.
- Author
-
Hussar, Daniel A.
- Subjects
- *
THERAPEUTIC use of monoclonal antibodies , *ANTIDOTES , *ANTIVIRAL agents , *COMBINATION drug therapy , *CURARE-like agents , *DRUG interactions , *DRY eye syndromes , *GOUT , *HEPATITIS C , *MONOCLONAL antibodies , *NEUROMUSCULAR blocking agents , *TYPE 2 diabetes , *NURSING practice , *PATIENT education , *PSORIASIS , *SELF medication , *CONTINUING education units , *URICOSURIC agents , *GLUCAGON-like peptide-1 agonists , *THERAPEUTICS - Abstract
The article offers information about the drugs approved by the U.S. Food and Drug Administration (FDA) as of July 2017, including Lixisenatide marketed as Adlyxin by Sanofi, Lesinurad marketed as Zurampic by Ironwood, and Ixekizumab marketed as Taltz by Lilly.
- Published
- 2017
- Full Text
- View/download PDF